Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TIAZAC vs AMVAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, resulting in coronary vasodilation, peripheral vasodilation, decreased myocardial contractility, and decreased AV nodal conduction velocity.
AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.
Hypertension,Chronic stable angina pectoris,Atrial fibrillation or atrial flutter (rate control),Paroxysmal supraventricular tachycardia (PSVT)
FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Oral: 120-360 mg once daily; maximum 540 mg daily.
Intravenous: 500 mg every 6 hours.
Terminal elimination half-life is 5-7 hours for immediate-release; for TIAZAC (extended-release), effective half-life is approximately 6-9 hours due to prolonged absorption
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Hepatic via CYP3A4 isoenzyme; extensive first-pass metabolism; metabolites include N-desmethyl diltiazem (active) and others.
AMVAZ is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Renal (2-4% unchanged, 60% as inactive metabolites); Fecal (30%); Biliary (minor)
Primarily renal excretion of unchanged drug (60-70%) and metabolites (10-20%); biliary/fecal excretion accounts for 15-25%.
70-80% bound to plasma proteins (albumin)
98% bound to albumin primarily, with minor binding to alpha-1-acid glycoprotein.
Approximately 1.7 L/kg; suggests extensive tissue distribution
0.2-0.3 L/kg, indicating minimal extravascular distribution and confinement to plasma volume.
Approximately 40% for oral immediate-release; extended-release formulation has comparable bioavailability with reduced peak-to-trough fluctuations
Oral bioavailability is 85-95%; reduced to 60-70% when taken with high-fat meals.
No specific adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min).
Cr Cl 30-50 m L/min: 250 mg every 6 hours; Cr Cl 15-29 m L/min: 250 mg every 12 hours; Cr Cl <15 m L/min: 250 mg every 24 hours; hemodialysis: 250 mg after dialysis.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce total dose by 50%; Child-Pugh Class C: reduce total dose by 60-70%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Not established; use in children <18 years is not recommended.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Start at lower end of dosing range (120 mg daily); titrate slowly due to increased sensitivity and potential for hypotension.
Consider renal function; start at lower end of dosing range due to age-related decreased renal clearance.
None
None
Bradycardia and heart block (risk increased with beta-blockers or digoxin),Heart failure with reduced ejection fraction (may worsen in acute MI or pulmonary congestion),Hypotension,Increased risk of gastrointestinal bleeding in elderly,Hepatic impairment (dose adjustment may be required),Abrupt withdrawal may exacerbate angina or cause rebound hypertension,Concurrent use with CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) increases diltiazem levels
Infusion-related reactions (IRRs): premedicate and monitor during infusion; interrupt or discontinue if severe.,Interstitial lung disease (ILD)/pneumonitis: monitor for new or worsening respiratory symptoms; withhold or permanently discontinue.,Dermatologic adverse reactions (rash, dry skin, pruritus): manage with topical corticosteroids, emollients, and oral antihistamines; consider dose modification.,Ocular toxicity: monitor for keratitis, uveitis; refer to ophthalmology if symptoms develop.,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception.
Sick sinus syndrome (unless paced),Second- or third-degree AV block (unless paced),Hypotension (systolic < 90 mm Hg),Cardiogenic shock,Atrial fibrillation/flutter with accessory bypass tract (e.g., Wolff-Parkinson-White syndrome, Lown-Ganong-Levine syndrome),Acute myocardial infarction with pulmonary congestion,Hypersensitivity to diltiazem
None
Avoid grapefruit juice and grapefruit products due to CYP3A4 inhibition, which can increase diltiazem levels. Limit sodium intake as part of hypertension management. No significant interaction with other foods.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing amiodarone levels and risk of toxicity. Limit alcohol consumption due to potential hepatotoxicity. High-fat meals may increase absorption; take consistently with or without food.
TIAZAC (diltiazem) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies have shown embryotoxic and teratogenic effects at high doses. Second and third trimesters: No well-controlled studies; risk of fetal bradycardia, hypotension, and hypocalcemia due to calcium channel blockade. Use only if benefit outweighs risk.
No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters: no known fetal harm.
Diltiazem is excreted into human breast milk at low concentrations. The milk-to-plasma ratio is approximately 0.4 to 0.8. Relative infant dose is estimated to be <1% of maternal weight-adjusted dose; considered compatible with breastfeeding. Monitor infant for potential adverse effects such as bradycardia, hypotension, or sedation.
No data on excretion in human milk; M/P ratio unknown. Caution recommended; benefits of breastfeeding should be weighed against potential risk to infant.
Pregnancy may alter the pharmacokinetics of diltiazem due to increased plasma volume, renal clearance, and hepatic metabolism. Dose adjustments may be necessary; titrate to clinical effect. No specific dosing guidelines; use the lowest effective dose and monitor blood pressure and heart rate closely.
No specific dose adjustments required in pregnancy; pharmacokinetic changes not well-characterized. Use lowest effective dose and monitor clinical response.
TIAZAC (diltiazem extended-release) is a nondihydropyridine calcium channel blocker used for hypertension and stable angina. Avoid use in patients with sick sinus syndrome or second/third-degree AV block without a pacemaker. It is a substrate of CYP3A4; monitor for interactions with strong inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin). In hepatic impairment, start at lowest dose. Use with beta-blockers increases risk of bradycardia and heart failure. May cause gingival hyperplasia; stress good oral hygiene.
AMVAZ (amiodarone) has a long half-life (up to 107 days) and can cause thyroid, pulmonary, hepatic, and skin toxicity. Monitor thyroid function (TSH, T3, T4), liver enzymes (ALT, AST), and perform baseline pulmonary function tests and chest X-ray. Corneal microdeposits are common and may cause visual halos; usually reversible. Administer loading dose to achieve therapeutic effect more quickly. Avoid use with grapefruit juice as it increases drug levels.
Take TIAZAC exactly as prescribed, usually once daily. Swallow the capsule whole; do not crush, chew, or open.,Do not stop taking this medication abruptly, as it may worsen chest pain or blood pressure.,Avoid drinking grapefruit juice or eating grapefruit while on this drug, as it can increase side effects.,Common side effects include dizziness, headache, swelling in the ankles/feet, and constipation. Contact your doctor if you experience very slow heartbeat, fainting, or shortness of breath.,Inform your doctor about all other medications, especially beta-blockers, digoxin, or other blood pressure drugs.
Take AMVAZ exactly as prescribed; do not stop without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking this medication.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations immediately.,Notify your doctor if you experience vision changes, yellowing of skin/eyes, dark urine, or unusual fatigue.,Use effective contraception during treatment and for at least 6 months after stopping.,Avoid excessive sun exposure; use sunscreen and protective clothing due to risk of skin discoloration and photosensitivity.,Do not take over-the-counter medications or herbal supplements without checking with your doctor.,Regular blood tests and eye exams are necessary while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TIAZAC vs AMVAZ, answered by our medical review team.
TIAZAC is a Calcium Channel Blocker that works by Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, resulting in coronary vasodilation, peripheral vasodilation, decreased myocardial contractility, and decreased AV nodal conduction velocity.. AMVAZ is a Calcium Channel Blocker that works by AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TIAZAC and AMVAZ depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TIAZAC is: Oral: 120-360 mg once daily; maximum 540 mg daily.. The standard adult dose of AMVAZ is: Intravenous: 500 mg every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TIAZAC and AMVAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TIAZAC is classified as Category C. TIAZAC (diltiazem) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies have shown embryotoxic and teratogenic effects at high doses. Seco. AMVAZ is classified as Category C. No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.